Advertisement
Advertisement

XENE

XENE logo

Xenon Pharmaceuticals Inc

55.66
USD
Sponsored
+0.09
+0.15%
Mar 26, 11:42 UTC -4
Open

XENE Earnings Reports

Positive Surprise Ratio

XENE beat 23 of 41 last estimates.

56%

Next Report

Date of Next Report
May 11, 2026
Estimate for Q1 26 (Revenue/ EPS)
--
/
-$1.21
Implied change from Q4 25 (Revenue/ EPS)
--
/
-7.63%
Implied change from Q1 25 (Revenue/ EPS)
-100.00%
/
+45.78%

Xenon Pharmaceuticals Inc earnings per share and revenue

On Feb 26, 2026, XENE reported earnings of -1.31 USD per share (EPS) for Q4 25, missing the estimate of -1.21 USD, resulting in a -7.79% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -3.76% price change (close before vs. close after earnings).
Looking ahead to Q1 26, 13 analysts forecast an EPS of -1.21 USD, with revenue projected to reach -- USD, implying an decrease of -7.63% EPS, and increase of 0.00% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Celcuity Inc. Common Stock
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$1.06
Actual
-$0.97
Surprise
+8.72%
logo
Precigen, Inc. Common Stock
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$0.08
Actual
-$0.01
Surprise
+88.24%
logo
Absci Corporation Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.19
Actual
-$0.23
Surprise
-16.04%
logo
Candel Therapeutics, Inc. Common Stock
Report Date
Mar 26, 2026 For Q4 25
Estimate
-$0.25
Actual
-$0.54
Surprise
-115.31%
logo
LENZ Therapeutics, Inc. Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.99
Actual
-$1.15
Surprise
-17.10%
logo
Fennec Pharmaceuticals Inc. Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
$0.03
Actual
-$0.11
Surprise
-408.12%
logo
Equillium, Inc. Common Stock
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$0.06
Actual
-$0.04
Surprise
+35.28%
logo
MaxCyte, Inc. Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.08
Actual
-$0.06
Surprise
+26.47%
logo
TELA Bio, Inc. Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.18
Actual
-$0.16
Surprise
+14.12%
logo
Dyadic International, Inc.
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$0.04
Actual
-$0.06
Surprise
-30.72%
FAQ
For Q4 2025, Xenon Pharmaceuticals Inc reported EPS of -$1.31, missing estimates by -7.79%, and revenue of $0.00, 0% as expectations.
The stock price moved down -3.76%, changed from $44.92 before the earnings release to $43.23 the day after.
The next earning report is scheduled for May 11, 2026.
Based on 13 analysts, Xenon Pharmaceuticals Inc is expected to report EPS of -$1.21 and revenue of -- for Q1 2026.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement